Aurobindo Pharma gets first US nod for alfuzosin HCL
MUMBAI, Nov 19 (Reuters) - The U.S. Food and Drug Administration has tentatively approved Aurobindo Pharma Ltd's (ARBN.BO: Quote, Profile, Research) alfuzosin hydrochloride extended release tablets, the regulator's website showed.
The drug is used to treat a non-cancerous enlarged prostate condition. (Reporting by Bharghavi Nagaraju; Editing by Ramya Venugopal)
© Thomson Reuters 2009 All rights reserved
Dubai Debt Fears
Banks outside the Gulf played down their exposure to Dubai debt, after fears the emirate could default and even derail world economic recovery prompted a sell-off in global markets. Full Article | Slideshow
One Year Later
Mumbai held tearful memorials and police staged a show of strength as it marked the first anniversary of militant raids that killed 166 people and pushed up tensions with Pakistan. Slideshow | Full Coverage
